You are here
Tetravalent bispecific fusion antibody for immunotherapy
Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA110297-01
Agency Tracking Number: CA110297
Amount:
$134,285.00
Phase:
Phase I
Program:
SBIR
Solicitation Topic Code:
N/A
Solicitation Number:
PHS2004-2
Timeline
Solicitation Year:
2004
Award Year:
2004
Award Start Date (Proposal Award Date):
N/A
Award End Date (Contract End Date):
N/A
Small Business Information
IMMUNOMEDICS, INC.
300 AMERICAN RD
MORRIS PLAINS, NJ
07950
United States
DUNS:
N/A
HUBZone Owned:
No
Woman Owned:
No
Socially and Economically Disadvantaged:
No
Principal Investigator
Name: ZHENGXING Qu
Phone: (973) 605-8200
Email: TQU@IMMUNOMEDICS.COM
Phone: (973) 605-8200
Email: TQU@IMMUNOMEDICS.COM
Business Contact
Name: CYNTHIA SULLIVAN
Phone: (973) 540-9595
Email: CSULLIVAN@IMMUNOMEDICS.COM
Phone: (973) 540-9595
Email: CSULLIVAN@IMMUNOMEDICS.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Immunotherapy based on a naked monoclonal antibody (mAb), such as rituximab, has emerged as a safe and effective modality for treatment of indolent and aggressive non-Hodgkin's lymphomas (NHL) and chronic lymphocytic
* Information listed above is at the time of submission. *